CME

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the first installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss the aryl hydrocarbon receptor (AhR) pathway and how AhR agonists work.

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the second installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, explain how tapinarof fits in the armamentarium for treating inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the third installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, describe the importance of skin barrier maintenance in treating inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the fourth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, discuss how topical therapies can be used to control inflammation and how to talk about that with patients.

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the fifth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, talk about the challenges involved with setting treatment goals with inflammatory dermatoses.

Host: Neal Bhatia, MD, FAAD

Guest: Joshua Grosshandler, MD, FAAD

In the sixth installment of this six-part series, Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Joshua Grosshandler, MD, FAAD, speculate about normalization of pigment as a potential benefit of aryl hydrocarbon receptor agonism.

Faculty: Jonathan Barratt, MD, PhD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Jonathan Barratt, MD, PhD

Faculty: An De Vriese, MD, PhD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Jonathan Barratt, MD, PhD

Faculty: An De Vriese, MD, PhD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Jonathan Barratt, MD, PhD

Faculty: Jörg Latus, MD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.